The Experts below are selected from a list of 14622 Experts worldwide ranked by ideXlab platform
E Kapiteijn - One of the best experts on this subject based on the ideXlab platform.
-
preoperative radiotherapy combined with Total Mesorectal Excision for resectable rectal cancer
The New England Journal of Medicine, 2001Co-Authors: E Kapiteijn, Willem H Steup, Corrie A.m. Marijnen, H.j.t. Rutten, Theo Wiggers, Lars Pahlman, Iris D Nagtegaal, Hein Putter, Bengt Glimelius, Han J Van KriekenAbstract:BACKGROUND: Short-term preoperative radiotherapy and Total Mesorectal Excision have each been shown to improve local control of disease in patients with resectable rectal cancer. We conducted a multicenter, randomized trial to determine whether the addition of preoperative radiotherapy increases the benefit of Total Mesorectal Excision. METHODS: We randomly assigned 1861 patients with resectable rectal cancer either to preoperative radiotherapy (5 Gy on each of five days) followed by Total Mesorectal Excision (924 patients) or to Total Mesorectal Excision alone (937 patients). The trial was conducted with the use of standardization and quality-control measures to ensure the consistency of the radiotherapy, surgery, and pathological techniques. RESULTS: Of the 1861 patients randomly assigned to one of the two treatment groups, 1805 were eligible to participate. The overall rate of survival at two years among the eligible patients was 82.0 percent in the group assigned to both radiotherapy and surgery and 81.8 percent in the group assigned to surgery alone (P=0.84). Among the 1748 patients who underwent a macroscopically complete local resection, the rate of local recurrence at two years was 5.3 percent. The rate of local recurrence at two years was 2.4 percent in the radiotherapy-plus-surgery group and 8.2 percent in the surgery-only group (P<0.001). CONCLUSIONS: Short-term preoperative radiotherapy reduces the risk of local recurrence in patients with rectal cancer who undergo a standardized Total Mesorectal Excision.
-
Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer
The New England Journal of Medicine, 2001Co-Authors: E Kapiteijn, Willem H Steup, Corrie A.m. Marijnen, H.j.t. Rutten, Theo Wiggers, Lars Pahlman, Iris D Nagtegaal, Hein Putter, Bengt Glimelius, J. Han Van KriekenAbstract:BACKGROUND: Short-term preoperative radiotherapy and Total Mesorectal Excision have each been shown to improve local control of disease in patients with resectable rectal cancer. We conducted a multicenter, randomized trial to determine whether the addition of preoperative radiotherapy increases the benefit of Total Mesorectal Excision. METHODS: We randomly assigned 1861 patients with resectable rectal cancer either to preoperative radiotherapy (5 Gy on each of five days) followed by Total Mesorectal Excision (924 patients) or to Total Mesorectal Excision alone (937 patients). The trial was conducted with the use of standardization and quality-control measures to ensure the consistency of the radiotherapy, surgery, and pathological techniques. RESULTS: Of the 1861 patients randomly assigned to one of the two treatment groups, 1805 were eligible to participate. The overall rate of survival at two years among the eligible patients was 82.0 percent in the group assigned to both radiotherapy and surgery and 81.8 percent in the group assigned to surgery alone (P=0.84). Among the 1748 patients who underwent a macroscopically complete local resection, the rate of local recurrence at two years was 5.3 percent. The rate of local recurrence at two years was 2.4 percent in the radiotherapy-plus-surgery group and 8.2 percent in the surgery-only group (P
Han J Van Krieken - One of the best experts on this subject based on the ideXlab platform.
-
preoperative radiotherapy combined with Total Mesorectal Excision for resectable rectal cancer
The New England Journal of Medicine, 2001Co-Authors: E Kapiteijn, Willem H Steup, Corrie A.m. Marijnen, H.j.t. Rutten, Theo Wiggers, Lars Pahlman, Iris D Nagtegaal, Hein Putter, Bengt Glimelius, Han J Van KriekenAbstract:BACKGROUND: Short-term preoperative radiotherapy and Total Mesorectal Excision have each been shown to improve local control of disease in patients with resectable rectal cancer. We conducted a multicenter, randomized trial to determine whether the addition of preoperative radiotherapy increases the benefit of Total Mesorectal Excision. METHODS: We randomly assigned 1861 patients with resectable rectal cancer either to preoperative radiotherapy (5 Gy on each of five days) followed by Total Mesorectal Excision (924 patients) or to Total Mesorectal Excision alone (937 patients). The trial was conducted with the use of standardization and quality-control measures to ensure the consistency of the radiotherapy, surgery, and pathological techniques. RESULTS: Of the 1861 patients randomly assigned to one of the two treatment groups, 1805 were eligible to participate. The overall rate of survival at two years among the eligible patients was 82.0 percent in the group assigned to both radiotherapy and surgery and 81.8 percent in the group assigned to surgery alone (P=0.84). Among the 1748 patients who underwent a macroscopically complete local resection, the rate of local recurrence at two years was 5.3 percent. The rate of local recurrence at two years was 2.4 percent in the radiotherapy-plus-surgery group and 8.2 percent in the surgery-only group (P<0.001). CONCLUSIONS: Short-term preoperative radiotherapy reduces the risk of local recurrence in patients with rectal cancer who undergo a standardized Total Mesorectal Excision.
J. Han Van Krieken - One of the best experts on this subject based on the ideXlab platform.
-
Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer
The New England Journal of Medicine, 2001Co-Authors: E Kapiteijn, Willem H Steup, Corrie A.m. Marijnen, H.j.t. Rutten, Theo Wiggers, Lars Pahlman, Iris D Nagtegaal, Hein Putter, Bengt Glimelius, J. Han Van KriekenAbstract:BACKGROUND: Short-term preoperative radiotherapy and Total Mesorectal Excision have each been shown to improve local control of disease in patients with resectable rectal cancer. We conducted a multicenter, randomized trial to determine whether the addition of preoperative radiotherapy increases the benefit of Total Mesorectal Excision. METHODS: We randomly assigned 1861 patients with resectable rectal cancer either to preoperative radiotherapy (5 Gy on each of five days) followed by Total Mesorectal Excision (924 patients) or to Total Mesorectal Excision alone (937 patients). The trial was conducted with the use of standardization and quality-control measures to ensure the consistency of the radiotherapy, surgery, and pathological techniques. RESULTS: Of the 1861 patients randomly assigned to one of the two treatment groups, 1805 were eligible to participate. The overall rate of survival at two years among the eligible patients was 82.0 percent in the group assigned to both radiotherapy and surgery and 81.8 percent in the group assigned to surgery alone (P=0.84). Among the 1748 patients who underwent a macroscopically complete local resection, the rate of local recurrence at two years was 5.3 percent. The rate of local recurrence at two years was 2.4 percent in the radiotherapy-plus-surgery group and 8.2 percent in the surgery-only group (P
Theo Wiggers - One of the best experts on this subject based on the ideXlab platform.
-
Technique for laparoscopic autonomic nerve preserving Total Mesorectal Excision
International journal of colorectal disease, 2005Co-Authors: Stephanie O. Breukink, Theo Wiggers, Jean-pierre E. N. Pierie, Christiaan Hoff, Wilhelmus J.h.j. MeijerinkAbstract:With the introduction of Total Mesorectal Excision (TME) for treatment of rectal cancer, the prognosis of patients with rectal cancer is improved. With this better prognosis, there is a growing awareness about the quality of life of patients after rectal carcinoma. Laparoscopic Total Mesorectal Excision (LTME) for rectal cancer offers several advantages in comparison with open Total Mesorectal Excision (OTME), including greater patient comfort and an earlier return to daily activities while preserving the oncologic radicality of the procedure. Moreover, laparoscopy allows good exposure of the pelvic cavity because of magnification and good illumination. The laparoscope seems to facilitate pelvic dissection including identification and preservation of critical structures such as the autonomic nervous system. The technique for laparoscopic autonomic nerve preserving Total Mesorectal Excision is reported. A three- or four-port technique is used. Vascular ligation, sharp Mesorectal dissection and identification and preservation of the autonomic pelvic nerves are described.
-
preoperative radiotherapy combined with Total Mesorectal Excision for resectable rectal cancer
The New England Journal of Medicine, 2001Co-Authors: E Kapiteijn, Willem H Steup, Corrie A.m. Marijnen, H.j.t. Rutten, Theo Wiggers, Lars Pahlman, Iris D Nagtegaal, Hein Putter, Bengt Glimelius, Han J Van KriekenAbstract:BACKGROUND: Short-term preoperative radiotherapy and Total Mesorectal Excision have each been shown to improve local control of disease in patients with resectable rectal cancer. We conducted a multicenter, randomized trial to determine whether the addition of preoperative radiotherapy increases the benefit of Total Mesorectal Excision. METHODS: We randomly assigned 1861 patients with resectable rectal cancer either to preoperative radiotherapy (5 Gy on each of five days) followed by Total Mesorectal Excision (924 patients) or to Total Mesorectal Excision alone (937 patients). The trial was conducted with the use of standardization and quality-control measures to ensure the consistency of the radiotherapy, surgery, and pathological techniques. RESULTS: Of the 1861 patients randomly assigned to one of the two treatment groups, 1805 were eligible to participate. The overall rate of survival at two years among the eligible patients was 82.0 percent in the group assigned to both radiotherapy and surgery and 81.8 percent in the group assigned to surgery alone (P=0.84). Among the 1748 patients who underwent a macroscopically complete local resection, the rate of local recurrence at two years was 5.3 percent. The rate of local recurrence at two years was 2.4 percent in the radiotherapy-plus-surgery group and 8.2 percent in the surgery-only group (P<0.001). CONCLUSIONS: Short-term preoperative radiotherapy reduces the risk of local recurrence in patients with rectal cancer who undergo a standardized Total Mesorectal Excision.
-
Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer
The New England Journal of Medicine, 2001Co-Authors: E Kapiteijn, Willem H Steup, Corrie A.m. Marijnen, H.j.t. Rutten, Theo Wiggers, Lars Pahlman, Iris D Nagtegaal, Hein Putter, Bengt Glimelius, J. Han Van KriekenAbstract:BACKGROUND: Short-term preoperative radiotherapy and Total Mesorectal Excision have each been shown to improve local control of disease in patients with resectable rectal cancer. We conducted a multicenter, randomized trial to determine whether the addition of preoperative radiotherapy increases the benefit of Total Mesorectal Excision. METHODS: We randomly assigned 1861 patients with resectable rectal cancer either to preoperative radiotherapy (5 Gy on each of five days) followed by Total Mesorectal Excision (924 patients) or to Total Mesorectal Excision alone (937 patients). The trial was conducted with the use of standardization and quality-control measures to ensure the consistency of the radiotherapy, surgery, and pathological techniques. RESULTS: Of the 1861 patients randomly assigned to one of the two treatment groups, 1805 were eligible to participate. The overall rate of survival at two years among the eligible patients was 82.0 percent in the group assigned to both radiotherapy and surgery and 81.8 percent in the group assigned to surgery alone (P=0.84). Among the 1748 patients who underwent a macroscopically complete local resection, the rate of local recurrence at two years was 5.3 percent. The rate of local recurrence at two years was 2.4 percent in the radiotherapy-plus-surgery group and 8.2 percent in the surgery-only group (P
Iris D Nagtegaal - One of the best experts on this subject based on the ideXlab platform.
-
preoperative radiotherapy combined with Total Mesorectal Excision for resectable rectal cancer
The New England Journal of Medicine, 2001Co-Authors: E Kapiteijn, Willem H Steup, Corrie A.m. Marijnen, H.j.t. Rutten, Theo Wiggers, Lars Pahlman, Iris D Nagtegaal, Hein Putter, Bengt Glimelius, Han J Van KriekenAbstract:BACKGROUND: Short-term preoperative radiotherapy and Total Mesorectal Excision have each been shown to improve local control of disease in patients with resectable rectal cancer. We conducted a multicenter, randomized trial to determine whether the addition of preoperative radiotherapy increases the benefit of Total Mesorectal Excision. METHODS: We randomly assigned 1861 patients with resectable rectal cancer either to preoperative radiotherapy (5 Gy on each of five days) followed by Total Mesorectal Excision (924 patients) or to Total Mesorectal Excision alone (937 patients). The trial was conducted with the use of standardization and quality-control measures to ensure the consistency of the radiotherapy, surgery, and pathological techniques. RESULTS: Of the 1861 patients randomly assigned to one of the two treatment groups, 1805 were eligible to participate. The overall rate of survival at two years among the eligible patients was 82.0 percent in the group assigned to both radiotherapy and surgery and 81.8 percent in the group assigned to surgery alone (P=0.84). Among the 1748 patients who underwent a macroscopically complete local resection, the rate of local recurrence at two years was 5.3 percent. The rate of local recurrence at two years was 2.4 percent in the radiotherapy-plus-surgery group and 8.2 percent in the surgery-only group (P<0.001). CONCLUSIONS: Short-term preoperative radiotherapy reduces the risk of local recurrence in patients with rectal cancer who undergo a standardized Total Mesorectal Excision.
-
Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer
The New England Journal of Medicine, 2001Co-Authors: E Kapiteijn, Willem H Steup, Corrie A.m. Marijnen, H.j.t. Rutten, Theo Wiggers, Lars Pahlman, Iris D Nagtegaal, Hein Putter, Bengt Glimelius, J. Han Van KriekenAbstract:BACKGROUND: Short-term preoperative radiotherapy and Total Mesorectal Excision have each been shown to improve local control of disease in patients with resectable rectal cancer. We conducted a multicenter, randomized trial to determine whether the addition of preoperative radiotherapy increases the benefit of Total Mesorectal Excision. METHODS: We randomly assigned 1861 patients with resectable rectal cancer either to preoperative radiotherapy (5 Gy on each of five days) followed by Total Mesorectal Excision (924 patients) or to Total Mesorectal Excision alone (937 patients). The trial was conducted with the use of standardization and quality-control measures to ensure the consistency of the radiotherapy, surgery, and pathological techniques. RESULTS: Of the 1861 patients randomly assigned to one of the two treatment groups, 1805 were eligible to participate. The overall rate of survival at two years among the eligible patients was 82.0 percent in the group assigned to both radiotherapy and surgery and 81.8 percent in the group assigned to surgery alone (P=0.84). Among the 1748 patients who underwent a macroscopically complete local resection, the rate of local recurrence at two years was 5.3 percent. The rate of local recurrence at two years was 2.4 percent in the radiotherapy-plus-surgery group and 8.2 percent in the surgery-only group (P
